TY - JOUR
T1 - Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma
T2 - Results of the population-based PHAROS-registry
AU - Oerlemans, Simone
AU - Issa, Djamila E
AU - van den Broek, Esther C
AU - Nijziel, Marten R
AU - Coebergh, Jan Willem W
AU - Huijgens, Peter C
AU - Mols, Floortje
AU - van de Poll-Franse, L.
PY - 2014
Y1 - 2014
N2 - The
increasing number of longer-living patients with diffuse large B-cell
lymphoma (DLBCL) and serious side effects of treatment urged us to study
the health-related quality of life (HRQoL) and persistent
(treatment-related) symptoms in unselected patients after different
treatment modalities and compare HRQoL of patients with a normative
population. The population-based Eindhoven Cancer Registry was used to
select all patients diagnosed with DLBCL from 2004 to 2010. The European
Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-year
interval. Detailed data on treatment were extracted from the
Population-based HAematological Registry for Observational Studies. Two
hundred fifty-six patients responded (84 %, T1). Compared to patients
treated with rituximab combined with cyclophosphamide, doxorubicin,
vincristine, and prednisone every 21 days ((R-)CHOP21), those who
underwent (R-)CHOP14 more often reported tingling in the hands and feet
(27 vs 42 %, p = 0.02) and fatigue (35 vs 46 %, p = 0.03)
and reported a lower global health status/HRQoL. Mean HRQoL was
statistically and clinically relevantly lower among DLBCL patients
compared to a normative population (p < 0.01).
Persistent tingling in hands/feet was reported more often by older
patients and patients treated with (R-)CHOP14 independently of the other
characteristics. Furthermore, patients who reported symptoms exhibited
significantly lower HRQoL compared to patients without symptoms/worries.
Patients treated with (R-)CHOP14 reported more neuropathic symptoms,
more fatigue, and a lower HRQoL than patients treated with (R-)CHOP21.
Alertness for persistent symptoms that occur during and after treatment
of DLBCL patients is needed and may help to avoid lasting negative
influence on their HRQoL.Keywords: Quality of life, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma, Cancer survivors, Population-based, Treatment, PHAROS, PROFILES
AB - The
increasing number of longer-living patients with diffuse large B-cell
lymphoma (DLBCL) and serious side effects of treatment urged us to study
the health-related quality of life (HRQoL) and persistent
(treatment-related) symptoms in unselected patients after different
treatment modalities and compare HRQoL of patients with a normative
population. The population-based Eindhoven Cancer Registry was used to
select all patients diagnosed with DLBCL from 2004 to 2010. The European
Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-year
interval. Detailed data on treatment were extracted from the
Population-based HAematological Registry for Observational Studies. Two
hundred fifty-six patients responded (84 %, T1). Compared to patients
treated with rituximab combined with cyclophosphamide, doxorubicin,
vincristine, and prednisone every 21 days ((R-)CHOP21), those who
underwent (R-)CHOP14 more often reported tingling in the hands and feet
(27 vs 42 %, p = 0.02) and fatigue (35 vs 46 %, p = 0.03)
and reported a lower global health status/HRQoL. Mean HRQoL was
statistically and clinically relevantly lower among DLBCL patients
compared to a normative population (p < 0.01).
Persistent tingling in hands/feet was reported more often by older
patients and patients treated with (R-)CHOP14 independently of the other
characteristics. Furthermore, patients who reported symptoms exhibited
significantly lower HRQoL compared to patients without symptoms/worries.
Patients treated with (R-)CHOP14 reported more neuropathic symptoms,
more fatigue, and a lower HRQoL than patients treated with (R-)CHOP21.
Alertness for persistent symptoms that occur during and after treatment
of DLBCL patients is needed and may help to avoid lasting negative
influence on their HRQoL.Keywords: Quality of life, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma, Cancer survivors, Population-based, Treatment, PHAROS, PROFILES
U2 - 10.1007/s00277-014-2099-8
DO - 10.1007/s00277-014-2099-8
M3 - Article
C2 - 24807105
SN - 0939-5555
VL - 93
SP - 1705
EP - 1715
JO - Annals of Hematology
JF - Annals of Hematology
IS - 10
ER -